Psychedelics Today

Download In this Episode, Joe interviews Brad Burge, Director of Strategic Communications at MAPS. In this episode they discuss the Phase 3 Trial for MDMA Assisted Psychotherapy, contradictions and Expanded Access. 3 Key Points: MAPS is about to run Phase 3 Trials of MDMA Assisted Psychotherapy If MDMA passes this third phase, it will still be tricky to get insurance involved. But the cost of one series of MDMA Therapy is much cheaper than a lifetime of typical pharmaceutical drugs and therapy sessions to heal PTSD. The only reason for-profit companies haven't gotten involved before was because there wasn't a promise on their investment. Finally, for-profit companies (like Compass Pathways) are interested in advancing these medicines (Psilocybin and MDMA). Support the show Patreon Leave us a review on iTunes Share us with your friends – favorite podcast, etc Join our Facebook group - Psychedelics Today group – Find the others and create community. Navigating Psychedelics Show Notes MAPS Brad Burge